Real-time Estimate
Cboe BZX
20:16:19 07/02/2025 GMT
5-day change
1st Jan Change
30.67 USD
-0.90%
-4.72%
+6.82%
Collegium Pharmaceutical Insider Sold Shares Worth $908,628, According to a Recent SEC Filing
January 14, 2025 at 09:22 pm
This article is reserved for members
Not a member ?
Free registration
Collegium Pharmaceutical, Inc. Appoints Nancy S. Lurker to Its Board of Directors
02-05
CI
Collegium Pharmaceutical Insider Sold Shares Worth $908,628, According to a Recent SEC Filing
01-14
MT
Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46
01-10
MT
Collegium Pharmaceutical Shares Rise After 2025 Guidance
01-08
MT
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.
01-08
CI
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2025
01-08
CI
Collegium Pharmaceutical, Inc., Q3 2024 Earnings Call, Nov 07, 2024
11-07
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q3 EPS $1.61
11-07
MT
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
11-07
CI
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.
11-07
CI
Collegium Pharmaceutical, Inc. Re-Affirms Earnings Guidance for the Full-Year 2024
11-07
CI
Collegium Pharmaceutical, Inc. Announces Chief Executive Officer Changes, Effective November 12, 2024
11-07
CI
Collegium Pharmaceutical, Inc. Announces Executive Changes, Effective November 12, 2024
11-07
CI
Collegium Pharmaceutical Insider Sold Shares Worth $773,792, According to a Recent SEC Filing
06/09/24
MT
BioPharma Credit notes Collegium's Ironshore acquisition
05/09/24
AN
BioPharma Credit Helps Fund Collegium Pharmaceutical's Acquisition of Ironshore Therapeutics
05/09/24
MT
Collegium Closes Acquisition of Ironshore Therapeutics; Boosts 2024 Product Revenue
04/09/24
MT
Collegium Pharmaceutical, Inc. Updates Financial Guidance for the Full Year 2024
04/09/24
CI
Collegium Pharmaceutical, Inc. completed the acquisition of Ironshore Therapeutics Inc.
03/09/24
CI
Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating
09/08/24
MT
Collegium Pharmaceutical, Inc., Q2 2024 Earnings Call, Aug 08, 2024
08/08/24
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.
08/08/24
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
08/08/24
CI
HC Wainwright Upgrades Collegium Pharmaceutical to Buy From Neutral, Price Target is $47
30/07/24
MT
Collegium Pharmaceutical, Inc., Ironshore Therapeutics Inc. - M&A Call
29/07/24
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
COLL: Dynamic Chart
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.
More about the company
Last Close Price
30.95 USD
Average target price
42.80 USD
Spread / Average Target
+38.29%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1